Sex hormone binding globulin is available on most comprehensive hormone panels, but it is not always included in standard ordering, and when it is left out, an important piece of the bioavailability picture goes missing with it. When SHBG is run, it is misread more often than almost any other value on the page. It gets treated as a hormone in its own right, chased up or down as though it were the imbalance itself, and folded into androgen or estrogen narratives that its own physiology does not support. SHBG is not a hormone. It is a transport protein synthesized in the liver, and its concentration is set by insulin, thyroid, and hepatic status long before sex steroids enter the picture. Treating the SHBG number directly means treating a readout rather than a driver, and the root cause can be missed in the process
SHBG determines how much testosterone or estradiol actually reaches tissue, which means a decision to start, adjust, or hold a hormone replacement protocol can be made on incomplete information if SHBG was never measured. A patient on transdermal estradiol whose SHBG is rising may need a dose conversation that has nothing to do with estrogen absorption. A patient started on testosterone therapy with an undiagnosed low SHBG may end up with more free androgen exposure than the total testosterone value alone suggests, and dosing decisions made without that context carry a risk of overshooting ot undershooting. Ordering SHBG alongside total and free hormone values, rather than assuming it is unnecessary, changes how confidently a practitioner can dose, titrate, and monitor a hormone protocol.
This piece builds the interpretive framework that separates SHBG the symptom from SHBG the signal, so the number becomes a diagnostic entry point rather than a target.
What SHBG Actually Is
SHBG is produced by hepatocytes and binds circulating testosterone and estradiol (it binds strongly and weakly with a number of other hormones but for the purpose of this article, we are going to focus on testosterone and estradiol) with high affinity. Only the unbound, or free, fraction of these hormones is biologically active at the tissue level. When SHBG rises, more hormones are bound and less is available to act. When SHBG falls, more hormones circulate in their free, active form, even if total hormone levels have not changed at all. This is why two patients with identical total testosterone can present with entirely different clinical pictures. The one with low SHBG may have more bioavailable androgen reaching tissue, while the one with high SHBG has less, regardless of what the total value on the page appears to say.
The clinical implication is that SHBG is best understood as a modifier of hormone exposure rather than a hormone source. It does not originate in the gonads and it is not regulated by the same feedback loops that govern estrogen, progesterone, or testosterone production. It is regulated upstream, primarily by hepatic metabolic status.
The Insulin Relationship Practitioners Get Backward
The most common error in SHBG interpretation is assuming that elevated insulin raises SHBG. The relationship runs in the opposite direction. Hyperinsulinemia suppresses hepatic SHBG production. The mechanism centers on hepatic lipogenesis, insulin and elevated glucose or fructose exposure downregulate hepatocyte nuclear factor 4 alpha, the transcription factor responsible for driving SHBG gene expression in the liver (Selva et al., 2007). As insulin resistance develops and hepatic lipogenic activity rises, SHBG output falls in parallel.
| CLINICAL PEARL — Low SHBG in a patient with normal fasting glucose can be an early sign of compensatory hyperinsulinemia, appearing well before glucose or HbA1c shift out of range. A SHBG value at the low end of the reference range deserves a fasting insulin and HOMA-IR before it is filed away as unremarkable. |
This mechanism is well established across the metabolic literature, and the direction of the relationship has been confirmed repeatedly. It is also the reason SHBG tracks so closely with insulin resistance and metabolic syndrome independent of body mass index. A lean patient with visceral adiposity or early insulin resistance can present with a low SHBG well before conventional metabolic markers move.
SHBG as a Thyroid Readout
Thyroid hormone also regulates hepatic SHBG synthesis, acting indirectly through the same hepatocyte nuclear factor 4 alpha pathway involved in the insulin relationship (Selva and Hammond, 2009). Hyperthyroidism raises SHBG. Hypothyroidism lowers it. This means a suppressed SHBG in a patient with sluggish thyroid function is not necessarily an androgen or metabolic story at all. It may simply be the liver’s response to inadequate thyroid signaling.
This relationship is not limited to endogenous thyroid disease. Thyroid hormone replacement itself raises SHBG as therapy is initiated and titrated toward euthyroid status, and the effect is dose dependent (Dumoulin, Perret, Bennet, and Caron, 1995). T3-containing preparations, including desiccated thyroid and liothyronine, tend to produce an even larger SHBG rise than T4-only therapy such as levothyroxine, because T3 acts more directly on hepatic SHBG production. In practice, this means a patient whose SHBG climbs after starting or increasing thyroid medication may simply be responding appropriately to treatment. It also means a patient who is over-replaced, with a suppressed TSH and thyroid hormone levels above what the body needs, can show an elevated SHBG as a downstream sign of that over-replacement, independent of any other hormone therapy the patient may be taking.
| CLINICAL PEARL — A low SHBG paired with a sluggish TSH and low-normal free T4 is often a thyroid story wearing an androgen mask. A high SHBG that appears shortly after a thyroid medication increase, particularly a T3-containing formulation, is worth checking against a current thyroid panel to ensure euthyroid status. Correcting the thyroid picture first prevents treating a downstream artifact instead of the upstream driver. |
SHBG as a Liver Readout
Because SHBG is synthesized exclusively in the liver, its concentration also reflects hepatic fat content and lipogenic activity directly, independent of the insulin and thyroid pathways described above. Hepatic steatosis suppresses SHBG production even in patients who are not overtly insulin resistant by conventional criteria, and the degree of suppression tends to exceed what body weight alone would predict. A SHBG that reads low relative to a patient’s overall metabolic presentation, particularly when weight and fasting glucose look unremarkable, is a reasonable prompt to look more closely at hepatic fat accumulation and lipid handling rather than assuming a purely hormonal explanation.
Treating the Number vs Treating the Driver
The clinical error that follows from misreading SHBG is treating the value itself. A practitioner sees a low SHBG, reads it as androgen excess, and reaches for interventions aimed at lowering free testosterone directly. If the actual driver is hyperinsulinemia, an undertreated thyroid, or early hepatic fat accumulation, the SHBG will not normalize and the underlying process continues unaddressed. Oral contraceptive and estrogen therapy use is well documented to raise SHBG substantially while a patient is taking it, since estrogen exposure stimulates hepatic SHBG output. This is a real and expected effect during use and possible longer. Panzer et al. (2006) found SHBG remained significantly elevated compared to never-users even >120 days after OC discontinuation.
The Clinical Approach to an Elevated SHBG
A high SHBG does not have a supplement or nutrient fix in the way that a nutrient deficiency has a repletion protocol. A handful of supplements are commonly recommended for lowering SHBG, and each has a plausible mechanistic story attached. Boron has been proposed to displace steroids from the SHBG binding site, nettle root contains a lignan that can displace testosterone from SHBG in cell culture, magnesium and zinc both have in vitro data suggesting they modulate SHBG binding affinity, and higher protein intake correlates with lower SHBG in observational cohorts. In practice, I have not seen these interventions translate into a reliable clinical effect. The boron data comes from a single small uncontrolled trial, the nettle root and magnesium findings are confined to in vitro binding studies with no confirmed effect on circulating SHBG in humans, and controlled trials of magnesium and zinc in women with PCOS have shown no significant change in SHBG. Vitamin D correlates with SHBG in the opposite direction and would not be a rational target for lowering it in any case. These options are worth knowing so a patient’s questions about them can be answered accurately and I think the risk of adding zinc, magnesium and protein for instance, is likely low risk for most patients, but none of them substitute for identifying and addressing the actual driver.
So, all of this makes an elevated SHBG a genuinely useful case for practicing differential thinking, and is worth walking through what that process looks like.
Confirm before you chase. A single elevated value deserves a retest before it drives any clinical decision, ideally on a fasting sample and, in menstruating women, timed to a consistent point in the cycle. A single number without a confirmatory draw is a weak foundation for a workup.
Review the medication list first. Before assuming an endogenous cause, ask what the patient is currently taking. Oral estrogen, whether in a contraceptive or a hormone therapy formulation, raises SHBG predictably. Thyroid hormone replacement raises it as well, particularly T3-containing preparations, and a recent dose increase is often enough to explain the shift on its own. Anticonvulsants are another recognized cause worth asking about directly.
Rule out over-replacement and hyperthyroidism. If the patient is on thyroid medication, a full thyroid panel, TSH, free T4, and free T3, clarifies whether the SHBG rise reflects appropriate treatment of hypothyroidism or over-replacement that needs a dose reduction. If the patient is not on thyroid medication, the same panel screens for undiagnosed hyperthyroidism as a primary driver.
Ask about weight, appetite, and intake. Low body weight, restrictive eating patterns, and significant recent weight loss are all associated with higher SHBG, and this history often does not surface unless it is asked about directly and without judgment.
Consider age and hepatic status. SHBG rises gradually with age in both sexes, so a modestly elevated value in an older patient may reflect normal aging physiology rather than a distinct pathology. Hepatic inflammation and impaired clearance can also raise SHBG in some contexts, which makes a basic hepatic panel a reasonable addition when the picture does not fit the more common drivers above.
The most useful question to start with is not how to lower the number, but what would cause the liver to produce more of this protein in this specific patient. That question redirects the workup toward medication history, thyroid status, body weight and intake, and age, rather than toward a supplement search the evidence does not support.
| CLINICAL PEARL — An elevated SHBG with no clear driver on medication review, thyroid panel, and weight history is uncommon. However, in practice there have been times where we have ruled out all known drivers and are still left with a high SHBG. |
Bringing This Into Practice
The functional reference ranges, the sequencing logic for differentiating insulin, thyroid, and hepatic contributions to an abnormal SHBG, and the decision-making that connects this marker to a complete female hormone workup are covered in full within Functional Hormone Mastery™. The program builds this framework into the broader female hormone assessment model, taking a practitioner from recognizing that SHBG has been misread to applying the correct differential with confidence.
References
Selva DM, Hogeveen KN, Innis SM, Hammond GL. Monosaccharide-induced lipogenesis regulates the human hepatic sex hormone-binding globulin gene. Journal of Clinical Investigation. 2007;117(12):3979-3987.
Selva DM, Hammond GL. Thyroid hormones act indirectly to increase sex hormone-binding globulin production by liver via hepatocyte nuclear factor-4alpha. Journal of Molecular Endocrinology. 2009;43(1):19-27.
Wallace IR, McKinley MC, Bell PM, Hunter SJ. Sex hormone binding globulin and insulin resistance. Clinical Endocrinology. 2013;78(3):321-329.
Dumoulin SC, Perret BP, Bennet AP, Caron PJ. Opposite effects of thyroid hormones on binding proteins for steroid hormones (sex hormone binding globulin and corticosteroid binding globulin) in humans. European Journal of Endocrinology. 1995;132(5):594-598.
